Literature DB >> 2412625

Bay K 8644, a dihydropyridine calcium agonist, augments vasoconstrictor responses to endogenous and exogenous noradrenaline in the peripheral vasculature of the dog.

T Goto, K Satoh, N Taira.   

Abstract

The effect of Bay K 8644 (a substance known to increase calcium influx through the voltage-dependent calcium channel) on vasoconstrictor responses of resistance vessels to endogenous and exogenous noradrenaline (NA) was investigated in pentobarbitone-anaesthetized dogs which had also undergone spinal anaesthesia and bilateral vagotomy and received atropine. In these dogs the saphenous arterial bed was perfused at fixed flow rates with autologous blood to give perfusion pressure close to the systemic blood pressure. Electrical stimulation (3-30 Hz) of the saphenous nerve and single intra-arterial (i.a.) injections of noradrenaline (NA, 0.03-3 micrograms) produced an increase in perfusion pressure (vasoconstriction) in a frequency- and a dose-dependent manner, respectively. Intra-arterial infusions of Bay K 8644 (3 and 10 micrograms min-1) per se produced no significant change in perfusion pressure. However, these infusions augmented vasoconstrictor responses to both saphenous nerve stimulation (endogenous NA) and i.a. NA (exogenous NA). These results suggest that augmentation by Bay K 8644 of vasoconstrictor responses of resistance vessels to endogenous and exogenous NA is probably due to promotion of the calcium influx through calcium channels closely associated with alpha-adrenoceptors in smooth muscle cells there.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2412625      PMCID: PMC1916661          DOI: 10.1111/j.1476-5381.1985.tb11091.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

1.  [Effect of nifedipine on the sympathetic nerve function of the heart].

Authors:  K Starke; H J Schümann
Journal:  Arzneimittelforschung       Date:  1973-02

2.  Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels.

Authors:  M Schramm; G Thomas; R Towart; G Franckowiak
Journal:  Nature       Date:  1983 Jun 9-15       Impact factor: 49.962

3.  The mechanism of inhibitory action of diltiazem on vascular smooth muscle contractility.

Authors:  C van Breemen; O Hwang; K D Meisheri
Journal:  J Pharmacol Exp Ther       Date:  1981-08       Impact factor: 4.030

4.  Interactions between the putative calcium entry promotor Bay k 8644 and pressor responses produced by alpha 1- and alpha 2-adrenoceptor agonists in the pithed normotensive rat.

Authors:  B Wilffert; P N van Heiningen; M J Mathy; A de Jonge; M J Thoolen; P B Timmermans; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-11       Impact factor: 3.000

5.  Activation of calcium channels by novel 1,4-dihydropyridines. A new mechanism for positive inotropics or smooth muscle stimulants.

Authors:  M Schramm; G Thomas; R Towart; G Franckowiak
Journal:  Arzneimittelforschung       Date:  1983

6.  Effects of Ca antagonists on Ca fluxes in resistance vessels.

Authors:  C Cauvin; K Saida; C van Breemen
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

7.  Agonist actions of Bay K 8644, a dihydropyridine derivative, on the voltage-dependent calcium influx in smooth muscle cells of the rabbit mesenteric artery.

Authors:  Y Kanmura; T Itoh; H Kuriyama
Journal:  J Pharmacol Exp Ther       Date:  1984-12       Impact factor: 4.030

  7 in total
  2 in total

1.  Similarity and dissimilarity of the vasoconstrictor effects of Bay K 8644 on coronary, femoral, mesenteric and renal circulations of dogs.

Authors:  K Ishii; Y Sato; N Taira
Journal:  Br J Pharmacol       Date:  1986-06       Impact factor: 8.739

2.  Differential antagonism by Bay K 8644 of vasodilator effects of nifedipine, diltiazem, nicorandil and nitroglycerin in dog femoral circulation.

Authors:  Y Sato; K Ishii; N Taira
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.